...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New Phase 2 Trial
Reply New Message
Back To Forum List View

Well, not really new, but new since the last I checked the trial database.

A Study of ZEN003694 in People With Squamous Cell Lung Cancer

Sponsored by Memorial Sloan Kettering Cancer Center (Zenith is a collaborator)

25 pts, estimated completion 2 years. Does not appear to be a drug combination trial - and therefore I think this is the only ongoing trial to dose patients with Zen-3694 alone.

 

8 Recommendations
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply